Bielmann P, Brun D, Moorjani S, Gagnon M A, Tétreault L, Lupien P J
Int J Clin Pharmacol Biopharm. 1977 Apr;15(4):166-71.
The effects of tibric acid, clofibrate, and placebo were compared in type IV hyperlipidemic patients for a 6-month period. The patients were divided into two pathological level groups according to their baseline triglyceride levels. Compared to the placebo, both tibric acid and clofibrate reduced the mean serum triglyceride concentration in the high pathological level group; however, clofibrate was also effective in the low pathological level group. The effects on total cholesterol were less pronounced with the two drugs. No effect was observed on esterified cholesterol, phospholipids, free fatty acids, and fasting blood sugar. After a 6-week follow-up period under placebo, no rebound of the triglyceride and cholesterol levels could be observed after discontinuation of the two active drugs. The other biochemical changes observed after each active treatment are discussed in relation to the different degree of activity of each active drug and to the different baseline levels of triglycerides.
在IV型高脂血症患者中比较了安妥明、氯贝丁酯和安慰剂的疗效，为期6个月。根据患者的基线甘油三酯水平将其分为两个病理水平组。与安慰剂相比，安妥明和氯贝丁酯均降低了高病理水平组的平均血清甘油三酯浓度；然而，氯贝丁酯在低病理水平组中也有效。两种药物对总胆固醇的影响不太明显。未观察到对酯化胆固醇、磷脂、游离脂肪酸和空腹血糖的影响。在安慰剂治疗6周的随访期后，停用两种活性药物后未观察到甘油三酯和胆固醇水平的反弹。根据每种活性药物的不同活性程度以及甘油三酯的不同基线水平，讨论了每次活性治疗后观察到的其他生化变化。
